Topiramate exposure in early pregnancy is linked to higher rates of major malformations and more specifically to increased risk of oral clefts, with risk rising at higher doses.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
Using valproic acid (Depakote) during pregnancy raises important safety concerns, including increased risks of congenital malformations and neurodevelopmental disorders.
Despite FDA warnings, valproate is still prescribed to women of reproductive age, placing children at risk for birth defects and neurodevelopmental disorders.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
Prenatal exposure to valproate is linked to increased risk of autism spectrum disorder, ADHD, lower IQ, and intellectual disability, especially at higher doses.
Folic Acid Awareness Week (Sept 7–14, 2025) focuses on the importance of daily folic acid supplements for women to prevent birth defects, as diet alone is often insufficient.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; Dr. Freeman weighs in on the information provided in the report.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
While we have adequate data to support the use of SSRI and SNRI antidepressants during pregnancy, there is less data regarding other classes of antidepressants. Although we less commonly use mirtazapine in pregnancy, several [...]
